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767Abstracts
WTP provides monetary estimate of over all beneﬁt of TB 
prevention and treatment program. The study results suggest
socio-economic factors and knowledge about TB as major deter-
minants of WTP.
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OBJECTIVES: Lipodystrophy may have a great impact on
quality of life (QoL). Current HIV speciﬁc instruments do not
measure this impact. We performed a cultural adaptation and
psychometric validation in French of a new lipodystrophy spe-
ciﬁc instrument Assessment of Body Change and Distress
(ABCD). METHODS: ABCD consists of three parts: signs of
lipodystrophy (6 items), global satisfaction (1 item) and 20 QoL
items. Items were generated in US. Our study consisted of two
parts: 1) Cultural adaptation; 2) Psychometric validation in a
survey in comparison with speciﬁc (MOS-HIV) and generic (SF-
12) QoL questionnaires. RESULTS: The approach of French
patients was to some extent different from US patients, and
needed cultural adaptation of several concepts. A total of 155
HIV French outpatients (143 with lipodystrophy) from 2
Parisian hospitals and one general practice were included. Mean
age was 43 ± 10yrs. Mean duration of HAART was 4.5 ± 1.7
yrs. Discriminant validity: QoL scores decreased according to the
number of sites with lipodystrophy, ranging from 85 ± 16 (none)
to 42 ± 10 (6 sites), p < 0.001, and according to whether patients
were thinking about plastic surgery or not, from 68 ± 20 (never)
to 33 ± 13 (always), p < 0.001. Internal consistency was high
(Cronbach alpha = 0.94). Factorial analysis yielded a 4-factor
structure. Convergent validity: the highest correlations were
between ABCD QoL and health distress and social dimensions
of the MOS-HIV (r > 0.6) and with the mental component of
the SF-12 (r = 0.65). CONCLUSIONS: The psychological and
social distress related to the body changes must be measured in
clinical trials, to make sure that life is not lengthened at the
expense of its quality. ABCD questionnaire is a validated ques-
tionnaire which can now be used in French.
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OBJECTIVES: Investigate the role economic evaluations played
in supporting decision making for meningococcal C conjugate
(MCC) vaccination. METHODS: We performed an extensive lit-
erature review (Pubmed, Embase, HEED, NEED) and contacted
experts to identify a) the incidence of meningococcal C disease,
and b) economic evaluations for MCC immunisation pro-
grammes and their inﬂuence on decision making. RESULTS:
Data were obtained for Australia, Canada, Israel, the US and 17
European countries. The yearly meningococcal C incidence per
100,000 persons varied between 0.04 (Italy) and 4.91 (Iceland)
in 2001. Ten countries have implemented MCC vaccination pro-
grammes. In all of them except Greece high meningococcal C
incidence was reported between 1999 and 2001 (one year ≥0.8
per 100,000) but economic evaluations were performed in only
four. While economic evaluation inﬂuenced decision making
strongly in Australia, Canada (Quebec) and The Netherlands, its
impact was limited in the UK. Of the 11 countries without MCC
vaccination programmes, only Portugal and Switzerland con-
ducted economic evaluations. These were performed after the
initial decision to not implement MCC vaccination was made,
but nonetheless (may) inform subsequent decision making in
both countries. All reviewed economic evaluations were model-
ling studies, each showing that routine childhood MCC vacci-
nation is slightly less effective but much more cost-effective early
in the second year of life (about 2500€ to 19,000€ per life-year
or QALY gained) than during the ﬁrst year of life (about 42,400€
to 2.4m€ per additionally gained life-year or QALY compared
to immunisation in the second year). The reported results were
most sensitive to meningococcal C incidence, vaccine price and
speciﬁc methodological characteristics. CONCLUSIONS: Only
in a minority of investigated countries economic evaluation of
MCC vaccination inﬂuenced decision making. The divergence
and importance of methodological characteristics in the analysed
studies demonstrates the need of ﬁrmer international guidelines
and better adherence to these guidelines.
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Some of the expected adverse drug reactions of the systemic tri-
azole antifungals (ﬂuconazole and itraconazole) can be attrib-
uted to drug-drug interactions. OBJECTIVES: To quantify the
frequency of concurrent drug use that may cause drug-drug inter-
actions (DDI) with triazole antifungals. METHODS: A retro-
spective observational study was conducted of adult patients
who received systemic triazole treatment in 6 hospitals compris-
ing the PHARMO Inpatient database during 1994–2002. The
list of triazole interacting drugs, the severity and effect of inter-
action was obtained from the Drug-Reax® system and the Drug
Interaction Facts. Concomitant use of triazole interacting drugs
was identiﬁed for each day of systemic triazole treatment.
RESULTS: The study cohort comprised 1374 patients with a
total of 1522 hospitalizations during which ﬂuconazole (n =
1329) or itraconazole (n = 193) were prescribed. The majority
of hospitalizations were for neoplasms (21.6%), respiratory
(15.2%) and digestive disease (14.3%). The median duration of
triazole treatment was eight days. Among patients receiving ﬂu-
conazole, 55.3% were prescribed at least one interacting drug
(>95% with potential for moderate or severe consequences) with
32.5% of patients receiving more than one interacting drug. The
most frequently co-prescribed interacting drugs with ﬂuconazole
were haloperidol, digoxin, prednisolone, acencoumarol and
theophylline. Among patients on itraconazole, 65.3% received
at least 1 interacting co-prescription (74% moderate or severe),
41% received more than one interacting drug. The most fre-
quently co-prescribed interacting drugs with itraconazole were
ranitidine, acenocoumarol, prednisolone, pantoprazole and
theophylline. The most frequent occurring effect of the DDI
